IL91933A - Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue - Google Patents
Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissueInfo
- Publication number
- IL91933A IL91933A IL9193389A IL9193389A IL91933A IL 91933 A IL91933 A IL 91933A IL 9193389 A IL9193389 A IL 9193389A IL 9193389 A IL9193389 A IL 9193389A IL 91933 A IL91933 A IL 91933A
- Authority
- IL
- Israel
- Prior art keywords
- conjugate
- agent
- tissue
- tumor
- delivery vehicle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25551388A | 1988-10-11 | 1988-10-11 | |
US41778289A | 1989-10-04 | 1989-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL91933A true IL91933A (en) | 1994-12-29 |
Family
ID=26944744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9193389A IL91933A (en) | 1988-10-11 | 1989-10-10 | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0438497B1 (ja) |
JP (1) | JP2961173B2 (ja) |
AT (1) | ATE135236T1 (ja) |
AU (1) | AU627785B2 (ja) |
DE (1) | DE68925974T2 (ja) |
IL (1) | IL91933A (ja) |
WO (1) | WO1990003801A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2171392T3 (es) * | 1990-08-29 | 2002-09-16 | Ct Hospitalier Regional De Nan | Poliligandos de proteina unidos a un nucleo de proteina estable. |
JPH09506761A (ja) * | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
AT409929B (de) * | 1997-03-07 | 2002-12-27 | Tritthart Helmut A Dr | Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung |
CA2219961C (en) * | 1998-01-09 | 2010-06-01 | The University Of Southern California | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
DE19824653A1 (de) * | 1998-02-25 | 1999-08-26 | Schering Ag | Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
JP4487019B2 (ja) | 1998-03-31 | 2010-06-23 | ランサス メディカル イメージング インコーポレイテッド | 血管新生疾患を画像化するための薬剤 |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
IL140700A0 (en) | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
AU766822B2 (en) | 1998-12-18 | 2003-10-23 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
WO2000035887A2 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6630120B1 (en) * | 1999-03-08 | 2003-10-07 | Alkermes, Inc. | Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors |
CA2380331C (en) | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
US6974791B2 (en) * | 2000-03-16 | 2005-12-13 | The University Of Pittsburgh | Endothelial specific targeting |
IT1318485B1 (it) * | 2000-04-21 | 2003-08-25 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20060222653A1 (en) * | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
JPS62501631A (ja) * | 1985-01-11 | 1987-07-02 | ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア | リポソ−ムの保持法 |
US4724212A (en) * | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-2 and diagnostic antibody produced thereby |
US4724213A (en) * | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-1 and diagnostic antibody produced thereby |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US4753895A (en) * | 1987-02-24 | 1988-06-28 | Hughes Aircraft Company | Method of forming low leakage CMOS device on insulating substrate |
-
1989
- 1989-10-10 IL IL9193389A patent/IL91933A/en not_active IP Right Cessation
- 1989-10-11 DE DE68925974T patent/DE68925974T2/de not_active Expired - Lifetime
- 1989-10-11 AU AU44245/89A patent/AU627785B2/en not_active Expired
- 1989-10-11 WO PCT/US1989/004513 patent/WO1990003801A1/en active IP Right Grant
- 1989-10-11 JP JP1511059A patent/JP2961173B2/ja not_active Expired - Lifetime
- 1989-10-11 EP EP89911955A patent/EP0438497B1/en not_active Expired - Lifetime
- 1989-10-11 AT AT89911955T patent/ATE135236T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0438497A1 (en) | 1991-07-31 |
WO1990003801A1 (en) | 1990-04-19 |
AU627785B2 (en) | 1992-09-03 |
AU4424589A (en) | 1990-05-01 |
DE68925974D1 (de) | 1996-04-18 |
JPH04503945A (ja) | 1992-07-16 |
EP0438497A4 (en) | 1992-02-26 |
JP2961173B2 (ja) | 1999-10-12 |
DE68925974T2 (de) | 1996-11-14 |
ATE135236T1 (de) | 1996-03-15 |
EP0438497B1 (en) | 1996-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU627785B2 (en) | Vasopermeability-enhancing conjugates | |
US5112954A (en) | Method of enhancing the effect of cytotoxic agents | |
US4997913A (en) | pH-sensitive immunoconjugates and methods for their use in tumor therapy | |
US4867973A (en) | Antibody-therapeutic agent conjugates | |
EP0175617A2 (en) | Antibody-therapeutic agent conjugates | |
JPH03503898A (ja) | 薬剤輸送系に関する更なる改良 | |
JPH06500563A (ja) | 調節された浄化時間を有する修飾抗体 | |
JPH01316329A (ja) | 機能的特異性抗体 | |
US6524823B2 (en) | Vasopermeability-enhancing conjugates | |
Shih et al. | Site‐specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier | |
Epstein et al. | Identification of a protein fragment of interleukin 2 responsible for vasopermeability | |
JP3340127B2 (ja) | 異常増殖性疾患措置のための抗体接合体 | |
US6403096B1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
Yang et al. | Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2. 27 conjugate directed to a human melanoma proteoglycan | |
Hara et al. | Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. | |
US5084560A (en) | Immunoconjugates and methods for their use in tumor therapy | |
EP0476408A1 (en) | Chemical conjugation of morpholino anthracyclines to antibodies | |
CA2000479C (en) | Vasopermeability-enhancing conjugates | |
Foxwell et al. | Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P | |
Sugiyama et al. | Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody | |
EP0334300A1 (en) | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites | |
Khawli et al. | Improving the chemotherapeutic index of IUdR using a vasoactive immunoconjugate | |
ES2218717T3 (es) | Peptido portenciador de la vasopermeabilidad de la interleuquina-2 humana e inmunoconjugados del mismo. | |
US20040156824A1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
WO1991000108A1 (en) | Antibody-oxidase conjugates with non-systemic substrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |